The Effects of 1-year Treatment with a Haemodiafiltration with On-line Regeneration of Ultrafiltrate (HFR) Dialysis on Biomarkers of Oxidative Stress in Patients with Chronic Renal Failure
Overview
Affiliations
In the last few years haemodiafiltration with on-line regeneration of ultrafiltrate (HFR) has been shown to have a positive impact on inflammation and oxidative stress biomarkers, but its effect on antioxidant levels and on oxidative damage to biomolecules in the long-term is still unknown. This is a randomised clinical study over 12 months involving 40 patients on haemodialysis, comparing the effect of HFR (n=25) dialysis with haemodialysis with polysulfone (HD-PS, n=15) on oxidative stress. Total antioxidant capacity, enzymatic antioxidant [superoxide dismutase (SOD), catalase and glutathione peroxidase], non-enzymatic (GSH) and biomarkers of oxidative stress (TBARs, carbonyl groups and 8-OH-dG) were evaluated. The antioxidant activity decreased in the lymphocytes of patients dialysed with HFR, with a significant decrease in the enzyme SOD. In the oxidative stress biomarkers, an increase was seen in the levels of 8-OH-dG in patients on HD-PS dialysis but not in those treated with HFR. Throughout the year the changes in antioxidant levels and biomarkers of oxidative damage in patients dialysed with HFR were generally more modest and fluctuated less than those dialysed with HD-PS. Our study indicates that, in general, long-term dialysis with HFR does not modified antioxidant parameters or increases the oxidative damage to biomolecules. The HFR showed to be a biocompatible technique for long-term dialysis.
Morisi N, Alfano G, Ferrarini M, Ferri C, Fontana F, Ballestri M J Nephrol. 2025; .
PMID: 40072829 DOI: 10.1007/s40620-025-02257-x.
Systemic Redox Imbalance in Chronic Kidney Disease: A Systematic Review.
Poulianiti K, Kaltsatou A, Mitrou G, Jamurtas A, Koutedakis Y, Maridaki M Oxid Med Cell Longev. 2016; 2016:8598253.
PMID: 27563376 PMC: 4987477. DOI: 10.1155/2016/8598253.
Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
Nistor I, Palmer S, Craig J, Saglimbene V, Vecchio M, Covic A Cochrane Database Syst Rev. 2015; (5):CD006258.
PMID: 25993563 PMC: 10766139. DOI: 10.1002/14651858.CD006258.pub2.
Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients.
Izquierdo M, Cavia M, Muniz P, de Francisco A, Arias M, Santos J BMC Nephrol. 2012; 13:159.
PMID: 23186077 PMC: 3520723. DOI: 10.1186/1471-2369-13-159.